Avelumab and Merkel Cell Carcinoma: Clinical Evidence Review

Legacy of General Health and Science Information

The legacy heritage of general health and science information has long emphasized the interconnectedness of bodily systems, where imbalances in one area can influence overall well-being. This foundational perspective, rooted in holistic principles, often guided public understanding of disease prevention and health maintenance. Within this broad context, discussions of therapeutic interventions and their potential downstream effects were framed as part of a continuum of care, focusing on patient outcomes and safety. Transitioning from this general health framework to a more specific occupational exposure concern requires a shift in focus. In mass production settings, workers may encounter various substances as part of their daily tasks, including those used in manufacturing processes. One such substance is Avelumab, a monoclonal antibody employed in therapeutic contexts, particularly for conditions like Merkel Cell Carcinoma. While Avelumab is primarily administered in clinical settings, its handling and potential exposure in industrial environments raise questions about occupational risk. The pivot here is from a patient-centered view of drug administration to a worker-centered view of unintended exposure. This transition acknowledges that the same agent, when encountered outside a controlled medical setting, may present different considerations for health surveillance and risk assessment. Thus, the legacy of general health information provides a basis for understanding biological interactions, while the new focus narrows to the specific scenario of occupational contact with Avelumab and its implications for Merkel Cell Carcinoma risk.

Bridge Transition: From General Health to Occupational Exposure

Building on the holistic principles of general health, we now focus on the specific context of occupational exposure to Avelumab. Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, EU, and Japan for the treatment of metastatic Merkel Cell Carcinoma (MCC), becoming the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC, showing that three out of five patients responded to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A retrospective study also examined ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC, noting that two agents—avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1)—are currently approved by the U.S. Food and Drug Administration for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Clinical Evidence and Risk Context

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing, with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAE) (https://pubmed.ncbi.nlm.nih.gov/31543781/). A reported case described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab can trigger immune-related adverse events, these may be manageable without discontinuation of therapy. Regarding causation considerations, the timeline between avelumab exposure and documented harm is relevant. In the reported case of hypercalcaemia due to sarcoidosis, the adverse event occurred during treatment with avelumab for metastatic MCC, suggesting a temporal relationship (https://pubmed.ncbi.nlm.nih.gov/31543781/). The mechanistic pathway linking avelumab to MCC is primarily through its role as an immune checkpoint inhibitor; by blocking PD-L1, avelumab enhances T-cell activity against tumor cells, which can also lead to immune overactivation and irAE (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, avelumab itself is not a cause of MCC but rather a treatment for it; the evidence does not indicate that avelumab causes MCC. Instead, the risk narrative centers on the adequacy of warnings regarding avelumab's adverse effects, including immune-related events, and the management of patients who become refractory to therapy. For affected patients, causation-related considerations include the potential for immune-related adverse events during avelumab treatment and the need for alternative therapies if progression occurs. The timeline between exposure and documented harm, such as irAE, can vary, but in the reported case, hypercalcaemia occurred during active treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/). The adequacy of warnings is supported by clinical trial data and case reports that inform prescribing information, though specific warning details are not provided in the evidence snippets. In summary, avelumab is an effective treatment for metastatic MCC, with response rates around one-third in chemotherapy-refractory patients. However, about half of patients may progress on therapy, and immune-related adverse events can occur. For avelumab-refractory patients, combination therapy with ipilimumab and nivolumab has shown some efficacy. The evidence does not support a causal link between avelumab and the development of MCC; rather, avelumab is used to treat MCC. Risk considerations focus on managing irAE and addressing treatment resistance.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence does not indicate that avelumab causes Merkel cell carcinoma (MCC). Avelumab is a treatment for MCC, not a cause. It is an immune checkpoint inhibitor that blocks PD-L1 to enhance T-cell activity against tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the risks of avelumab therapy?

Avelumab can cause immune-related adverse events (irAE) due to overactivation of the immune system. For example, a case reported hypercalcaemia secondary to reactivation of sarcoidosis in a patient on avelumab, which was managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, about 50% of patients with advanced MCC may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.